Phase 2 Trial of Cixutumumab in Children, Adolescents and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group

PURPOSE: This phase 2 study was designed to assess the efficacy of single agent cixutumumab (IMC-A12) and gain further information about associated toxicities and pharmacodynamics in children, adolescents, and young adults with recurrent or refractory solid tumors. PATIENTS AND METHODS: Patients wit...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pediatr Blood Cancer
Asıl Yazarlar: Weigel, Brenda, Malempati, Suman, Reid, Joel M., Voss, Stephan D., Cho, Steven Y., Chen, Helen X., Krailo, Mark, Villaluna, Doojduen, Adamson, Peter C., Blaney, Susan M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4511811/
https://ncbi.nlm.nih.gov/pubmed/23956055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24605
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller